Uncategorized
This week in Drug Discovery (6 – 10 April)

News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW.
This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration.
The top stories:
Research uncovers previously unknown recessive condition
Researchers have discovered how genetic mutations can cause neuro-developmental disorders, including a previously unknown recessive condition.
Trial to test CAR T-cell therapies as childhood cancer cures
A first-of-its-kind trial has launched to explore whether personalised CAR T-cell immunotherapy could treat childhood cancers.
FDA approves Lilly’s GLP-1 pill for weight loss
The US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.
AC Immune and Lilly reach agreement on drug collaboration
Biopharmaceutical company AC Immune has reached an amended agreement with Eli Lilly for the development of an Alzheimer’s treatment.
Read more…
Alzheon doses first patient with novel Alzheimer’s drug
The first patient has been dosed in Alzheon’s Phase I trial of its Alzheimer’s drug.
Read more…
The post This week in Drug Discovery (6 – 10 April) appeared first on Drug Discovery World (DDW).
Uncategorized
Amgen shores up Tavneos’ FDA defense with Duke data analysis
Amgen shores up Tavneos’ FDA defense with Duke data analysis
After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval. Read More
Uncategorized
Chile offers new data on food warning label efficacy
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.
Uncategorized
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win
The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform